{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:27:35Z","timestamp":1760866055166,"version":"3.41.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T00:00:00Z","timestamp":1490918400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s12072-017-9794-1","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T02:41:43Z","timestamp":1490928103000},"page":"277-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study"],"prefix":"10.1007","volume":"11","author":[{"given":"Sandeep Singh","family":"Sidhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmaljeet Singh","family":"Malhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omesh","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Grover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JS","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harmeet","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajesh","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gursewak","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsh","family":"Kishore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simran","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,31]]},"reference":[{"issue":"1","key":"9794_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77\u201387","journal-title":"Hepatology"},{"issue":"143","key":"9794_CR2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/0971-5916.182624","volume":"2016","author":"S Vasudevan","year":"2016","unstructured":"Vasudevan S, Shalimar Kavimandan A, Kalra N, Nayak B, Thakur B, Das P, et al. Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India. Indian J Med Res 2016;2016(143):331\u2013340","journal-title":"Indian J Med Res"},{"key":"9794_CR3","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/gut.2005.070649","volume":"54","author":"N Coppola","year":"2005","unstructured":"Coppola N, Vatiero LM, Sagnelli E. HCV genotype 2 as a risk factor for reactivation of chronic HCV infection. Gut. 2005;54:1207","journal-title":"Gut"},{"issue":"18","key":"9794_CR4","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1111\/j.1365-2893.2011.01441.x","volume":"2011","author":"G Nkontchou","year":"2011","unstructured":"Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepatol 2011;2011(18):e516\u2013e22","journal-title":"J Viral Hepatol"},{"issue":"51","key":"9794_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","volume":"2009","author":"PY Bochud","year":"2009","unstructured":"Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, Borovicka J, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;2009(51):655\u2013666","journal-title":"J Hepatol"},{"issue":"358","key":"9794_CR6","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"2001","author":"MP Manns","year":"2001","unstructured":"Manns MP, Mc Hutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus Ribavirin compared with Interferon alfa- 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;2001(358):958\u2013965","journal-title":"Lancet"},{"issue":"347","key":"9794_CR7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"2002","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, H\u00e4ussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;2002(347):975\u2013982","journal-title":"N Engl J Med"},{"issue":"140","key":"9794_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"2004","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;2004(140):346\u2013355","journal-title":"Ann Intern Med"},{"issue":"40","key":"9794_CR9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jhep.2004.02.007","volume":"2004","author":"S Zeuzem","year":"2004","unstructured":"Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;2004(40):993\u2013999","journal-title":"J Hepatol"},{"issue":"55","key":"9794_CR10","first-page":"245","volume":"2011","author":"European Association for the Study of the Liver","year":"2011","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis C virus infection. J Hepatol 2011;2011(55):245\u2013264","journal-title":"J Hepatol"},{"issue":"28","key":"9794_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2036.2008.03763.x","volume":"2008","author":"A Andriulli","year":"2008","unstructured":"Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008;2008(28):397\u2013404","journal-title":"Aliment Pharmacol Ther"},{"issue":"461","key":"9794_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"2009","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;2009(461):399\u2013401","journal-title":"Nature"},{"key":"9794_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0168-8278(13)60016-1","volume":"58","author":"E Gane","year":"2013","unstructured":"Gane E, Stedman C, Hyland R, Pang P, Ding X, Symonds W, McHutchison JG. All-oral sofosbuvir based 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study. J Hepatol 2013;58:6\u20137","journal-title":"J Hepatol"},{"issue":"368","key":"9794_CR14","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","volume":"2013","author":"I Jacobson","year":"2013","unstructured":"Jacobson I, Gordon S, Kowdley K, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;2013(368):1867\u20131877","journal-title":"N Engl J Med"},{"issue":"368","key":"9794_CR15","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"2013","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;2013(368):1878\u20131887","journal-title":"N Engl J Med"},{"issue":"370","key":"9794_CR16","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"2014","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;2014(370):1993\u20132001","journal-title":"N Engl J Med"},{"key":"9794_CR17","unstructured":"US Food and Drug Administration. India may soon get treatment for Hepatitis C. Jul 06, 2016.\u00a0 http:\/\/economictimes.indiatimes.com\/industry\/healthcare\/biotech\/pharmaceuticals\/india-may-soon-get-treatment-for-hepatic\/articleshow\/53075898.cms . Accessed 29 Dec 2016."},{"issue":"2","key":"9794_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2893.2008.01012.x","volume":"16","author":"S Zeuzem","year":"2009","unstructured":"Zeuzem S, Berg T, Moeller H, Hinrichsen H, Mauss S, Wedemeyer H, Sarrazin C, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009;16(2):75\u201390","journal-title":"J Viral Hepat."},{"issue":"149","key":"9794_CR19","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","volume":"2015","author":"GR Foster","year":"2015","unstructured":"Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, Barnes E, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C Virus genotype 2 infection. Gastroenterology. 2015;2015(149):1462\u20131470","journal-title":"Gastroenterology"},{"issue":"30","key":"9794_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijid.2014.09.021","volume":"2015","author":"H Aziz","year":"2015","unstructured":"Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. Int J Infect Dis 2015;2015(30):91\u201397","journal-title":"Int J Infect Dis"},{"key":"9794_CR21","doi-asserted-by":"crossref","unstructured":"Rembeck R, Lagging M. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection, A Review. Available at: http:\/\/www.futuremedicine.com\/doi\/pdf\/10.2217\/pgs.15.65 . Accessed 29 Dec 2016.","DOI":"10.2217\/pgs.15.65"},{"issue":"373","key":"9794_CR22","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"2015","author":"GR Foster","year":"2015","unstructured":"Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, Lawitz E, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 2015;2015(373):2608\u20132617.","journal-title":"N Engl J Med"},{"issue":"163","key":"9794_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.7326\/M15-1014","volume":"2015","author":"S Pianko","year":"2015","unstructured":"Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med 2015;2015(163):809\u2013817","journal-title":"Ann Intern Med"},{"key":"9794_CR24","unstructured":"Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman C, Davis MN, Hinestrosa F et al. Sofosbuvir\/Velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A-Containing DAA regimens: results of the retreatment study. In: 51st Annual meeting of the European association for the study of the liver (EASL). April 13\u201317, 2016; Barcelona, Spain, Apr 2016."},{"key":"9794_CR25","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. In: HCV guidance: recommendations for testing, managing, and treating hepatitis C Oct 2016. Available at: http:\/\/www.hcvguidelines.org\/full-report-view . Accessed 21 Dec 21 2016."}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-017-9794-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-017-9794-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-017-9794-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:52:34Z","timestamp":1750189954000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-017-9794-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,31]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["9794"],"URL":"https:\/\/doi.org\/10.1007\/s12072-017-9794-1","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"type":"print","value":"1936-0533"},{"type":"electronic","value":"1936-0541"}],"subject":[],"published":{"date-parts":[[2017,3,31]]}}}